Semefei, Pfizer and GSK jointly develop universal tumor detection

Source: Biostar technology announced on Thursday that it will work with GlaxoSmithKline and Pfizer to develop a generic tumor detection based on next-generation sequencing as a companion diagnosis for some drug programs After development and validation, Thermo Fisher plans to submit the test to the US FDA and other regulatory agencies This test will be developed on the ion PGM DX platform and will use ion AmpliSeq amplification technology Not long ago, Thermo Fisher just completed the declaration of ion PGM DX as a class II medical device The markers on this test will come from the Oncome cancer research panel of Thermo Fisher, which analyzes the single nucleotide variation, copy number variation, gene fusion, insertion and deletion of 143 oncogenes Of those genes, 26 are targeted by existing cancer drugs on the market, while 44 can be used to determine the recruitment of cancer patients in clinical trials According to reports, PGM platform and AmpliSeq technology can analyze hundreds of genes in tumor samples, and are compatible with a small number of starting materials, such as biopsy samples or fine needle aspiration samples "By working with Pfizer, GlaxoSmithKline and other potential pharmaceutical companies, we are looking for a paradigm shift and developing a generic next-generation sequencing test that provides a comprehensive analysis of multiple related genetic markers," said Dan Rhodes, director of oncology for Thermo Fisher Scientific solutions Just a month ago, Illumina announced a partnership with well-known pharmaceutical companies to develop a universal cancer detection system based on new generation sequencing (NGS) Early strategic partners of Illumina include AstraZeneca, Janssen biotech, Inc and Sanofi According to reports, Illumina is working with strategic partners to develop an analysis that can detect and measure multiple variants at the same time to support partners' clinical trials, with the goal of ensuring regulatory approval and commercialization of testing At the same time, Illumina also worked with key thought leaders to set standards for the analysis of ngs in daily clinical tumor practice and define regulatory framework to achieve this new detection mode In summary, the goal of Illumina and its strategic partners is to move from the concomitant diagnosis of a single analyte to panel based analysis to select "concomitant therapy" Dr Ellen v sigal, chairman and founder of friends of cancer research, believes that this type of cooperation will bring substantial progress to patients "These agreements represent in-depth collaboration between Illumina and the pharmaceutical industry to create technical, clinical, regulatory, and ultimately commercial solutions for a new generation of molecular oncology," said Rick Klausner, MD, Illumina's chief medical officer We are happy to work together to maximize the benefits for cancer patients "